sunitinib (Sutent)

From Aaushi
Jump to navigation Jump to search

Indications

Dosage

  • 50 mg PO QD for 4 weeks followed by 2 week drug holiday

Capsules: 12.5 mg, 25 mg or 50 mg

Adverse effects

Drug interactions

Laboratory

Mechanism of action

More general terms

References

  1. Prescriber's Letter 14(2): 2007 New drugs approved by the FDA in 2006 Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=2302213&pb=PRL (subscription needed) http://www.prescribersletter.com
  2. 2.0 2.1 FDA Medwatch http://www.fda.gov/medwatch/safety/2008/safety08.htm#Avastin
  3. Sutent http://www.sutent.com/
  4. National Cancer Institute: Sunitinib Malate http://www.cancer.gov/cancertopics/druginfo/sunitinibmalate
    Wikipedia: Sunitinib http://en.wikipedia.org/wiki/Sunitinib
  5. RxList Sutent http://www.rxlist.com/sutent-drug.htm
  6. 6.0 6.1 6.2 6.3 Medical Knowledge Self Assessment Program (MKSAP) 16, 17 American College of Physicians, Philadelphia 2012, 2015
  7. 7.0 7.1 Deprecated Reference
  8. 8.0 8.1 FDA News Release. November 16, 2017 FDA expands approval of Sutent to reduce the risk of kidney cancer returning. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm585657.htm